Selecta Biosciences. has filed a patent for synthetic nanocarrier compositions that contain immunosuppressants and MHC Class II-restricted epitopes of an allergen. These compositions aim to induce tolerogenic immune responses specific to the allergen. GlobalData’s report on Selecta Biosciences gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Selecta Biosciences Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Selecta Biosciences, Nanoparticle drug conjugates was a key innovation area identified from patents. Selecta Biosciences's grant share as of September 2023 was 20%. Grant share is based on the ratio of number of grants to total number of patents.

Synthetic nanocarrier composition for allergen-specific immune tolerance

Source: United States Patent and Trademark Office (USPTO). Credit: Selecta Biosciences Inc

A recently filed patent (Publication Number: US20230310593A1) describes a composition that includes two populations of synthetic nanocarriers. The first population is coupled to immunosuppressants, while the second population is coupled to MHC Class II-restricted epitopes of an allergen. The composition aims to reduce undesired immune responses to allergens in subjects.

The patent claims that the first and second populations of synthetic nanocarriers can be the same population. The immunosuppressants in the composition can include various agents such as statins, mTOR inhibitors, corticosteroids, and adenosine receptor agonists, among others.

The allergen in the composition is one that induces an undesired immune response in a subject. This response can manifest as allergen-specific antibody production or allergen-specific CD4+ T cell proliferation and/or activity. The allergen can be related to asthma, hay fever, hives, eczema, plant allergies, insect sting allergies, animal allergies, fungal allergies, drug allergies, pet allergies, latex allergies, mold allergies, cosmetic allergies, or food allergies.

The composition can have a range of immunosuppressants and/or epitopes on average across the synthetic nanocarriers, between 0.0001% and 50%. The synthetic nanocarriers can be lipid nanoparticles, polymeric nanoparticles, metallic nanoparticles, surfactant-based emulsions, dendrimers, buckyballs, nanowires, virus-like particles, or peptide or protein particles.

The size of the synthetic nanocarriers, as measured by dynamic light scattering, is greater than 100 nm on average. The aspect ratio of the synthetic nanocarriers can be greater than various ratios, such as 1:1, 1:1.2, 1:1.5, 1:2, 1:3, 1:5, 1:7, or 1:10.

The composition can also include a pharmaceutically acceptable excipient, and it can be formulated into a dosage form. Methods of administering the composition to a subject are described, as well as methods of reducing undesired immune responses to allergens in subjects.

The patent also covers methods of producing the composition, ensuring the absence of B cell epitopes in the second population of synthetic nanocarriers, and a process for producing the composition or dosage form.

Overall, this patent describes a composition and methods for reducing undesired immune responses to allergens using synthetic nanocarriers coupled with immunosuppressants and MHC Class II-restricted epitopes.

To know more about GlobalData’s detailed insights on Selecta Biosciences, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies